Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with a high metastatic potential. Treatment with chemotherapy can produce high response rates, but potential relapse rates are ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

The ADRIATIC study included 730 patients with stages I-III LS-SCLC who had not progressed after concurrent chemoradiotherapy. Participants were randomized to receive durvalumab, placebo ...

Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

"This is the largest retrospective study to assess and demonstrate that immune-related toxicity is positively associated with improved clinical outcomes in patients with ES-SCLC [extensive-stage ...

SCLC patients, particularly with high tumor burden, face significant ATLS risk, despite typically low overall risk in solid tumors. Early recognition and aggressive intervention are crucial, yet ...

The updated results will include additional patients and follow-up from the ongoing trial of ZL-1310 in patients with previously treated ES-SCLC after at least one prior platinum-based ...